{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008494","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.545407+00:00","generated_at":"2026-06-17T20:50:08.245767+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagenic Therapeutics announces 1-for-4 reverse stock split to comply with Nasdaq minimum bid price rule","bullets":["Reverse split effective 5:01 p.m. ET March 22, 2023; split-adjusted trading Nasdaq opens March 23, 2023.","Goal: meet Nasdaq Rule 5550(a)(2) $1.00 minimum closing price for continued listing.","Outstanding shares reduced from ~17,285,261 to ~4,321,315; no fractional shares—rounded up to next whole.","Proportionate adjustments to exercise prices and shares underlying outstanding options, warrants, and equity awards.","Authorized shares and par value unchanged; new CUSIP 74365N202; ticker remains PTIX."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008494","json":"https://secwatch.observer/filing/0001493152-23-008494.json","markdown":"https://secwatch.observer/filing/0001493152-23-008494.md","text":"https://secwatch.observer/filing/0001493152-23-008494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000149315223008494/0001493152-23-008494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000149315223008494/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:50:08.245767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dd6d8baf3f6211b1eaa7c13a4b424658b835d1b","claim":"Protagenic Therapeutics, Inc.new: Approved and filed a Certificate of Amendment to effect a 1-for-4 reverse stock split of common stock to comply with Nasdaq Rule 5550(a)(2) (effective 2023-03-22).","evidence_excerpt":"On March 21, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its third amended and restated certificate of incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000149315223008494/0001493152-23-008494-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}